NeuroBo Pharmaceuticals (NRBO) to Release Quarterly Earnings on Thursday

NeuroBo Pharmaceuticals (NASDAQ:NRBO) is anticipated to announce its earnings results on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.89) per share for the quarter.

NeuroBo Pharmaceuticals Trading Down 1.3 %

NeuroBo Pharmaceuticals stock opened at $1.57 on Thursday. NeuroBo Pharmaceuticals has a 52 week low of $2.08 and a 52 week high of $5.30. The firm’s 50-day simple moving average is $1.73 and its 200 day simple moving average is $2.33.

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity.